Turnstone Biologics (NASDAQ:TSBX – Free Report) had its price objective lowered by Piper Sandler from $20.00 to $3.75 in a research report report published on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.
Separately, Bank of America decreased their target price on Turnstone Biologics from $12.00 to $10.00 and set a buy rating on the stock in a report on Monday.
Check Out Our Latest Stock Report on TSBX
Turnstone Biologics Price Performance
Turnstone Biologics (NASDAQ:TSBX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.08). On average, research analysts expect that Turnstone Biologics will post -3.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Zimmer Partners LP boosted its position in Turnstone Biologics by 271.4% in the 1st quarter. Zimmer Partners LP now owns 179,026 shares of the company’s stock valued at $469,000 after buying an additional 130,826 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in shares of Turnstone Biologics during the first quarter valued at $111,000. Finally, Sei Investments Co. acquired a new position in shares of Turnstone Biologics during the second quarter valued at $31,000. Institutional investors own 52.51% of the company’s stock.
Turnstone Biologics Company Profile
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
Recommended Stories
- Five stocks we like better than Turnstone Biologics
- The 3 Best Fintech Stocks to Buy Now
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- Short Selling: How to Short a Stock
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- 3 Small Caps With Big Return Potential
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.